The ICOS-ICOSL co-stimulatory axis in cardiac fibrosis: distinct pathological outcomes following receptor vs. ligand inhibition

Clicks: 1
ID: 323496
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #271 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Cardiac fibroblasts are vital for cardiac damage repair, but their overactivation can lead to maladaptive fibrosis and heart failure. While the Inducible T-cell Co-Stimulator (ICOS) and its Ligand (ICOSL) are known to influence non-immune cells, their specific role in cardiac injury remains largely unexplored. Investigating how this signalling modulates fibroblast behaviour could reveal novel mechanisms to limit fibrosis and improve myocardial recovery. Purpose To investigate the role of the ICOS-ICOSL signalling in modulating fibroblast behaviour and cardiac fibrosis. Methods Six-month-old male Balb/C mice received Angiotensin II (Ang-II; 1.5 mg/kg/day) or saline via osmotic mini-pumps for 15 days. ICOS or ICOSL signalling was inhibited using monoclonal antibodies (150 µg/dose i.p., every 3 days). Mice were divided into six groups: Veh/Isotype (n=6), AngII/Isotype (n=16), Veh/anti-ICOS (n=7), AngII/anti-ICOS (n=16), Veh/anti-ICOSL (n=7), and AngII/anti-ICOSL (n=16). Echocardiography, histochemical characterisation, and qRT-PCR were performed to investigate the morpho-functional changes and molecular features of the heart. Results Combined Ang-II and either anti-ICOS or anti-ICOSL treatment markedly increased mortality rate (40-50%), compared to Ang-II (13%). The combination of Ang-II and ICOS or ICOSL inhibition significantly reduced systolic function, including ejection fraction (EF) and fractional shortening (FS), compared to controls. Notably, anti-ICOSL worsened cardiac remodelling, increasing relative wall thickness (RWT) and left ventricular remodelling index (LVRI), and reduced EF even as a monotherapy. Overall, myocardial fibrosis was increased in AngII/Isotype and AngII/anti-ICOSL groups, which was reflected by elevated CTGF (connective tissue growth factor) mRNA expression level; however, TGF-β (transforming growth factor-β) and Col1a1 (collagen type I alpha 1) expression were significantly increased only with anti-ICOSL. Differential collagen regulation was observed; anti-ICOS increased Col3a1 (collagen type III alpha 1) expression, whereas anti-ICOSL elevated Col1a1 expression and the Col1a1/Col3a1 ratio. Furthermore, the Ang-II-induced reduction in the Myh6/Myh7 ratio (hypertrophy marker) was minimised by anti-ICOS but accelerated by anti-ICOSL treatment. These findings were consistent with NPPB (natriuretic peptide B) expression and serum NT-proBNP levels, which remained significantly elevated in the AngII/anti-ICOSL group but were normalised in the AngII/anti-ICOS group. Conclusions ICOS-ICOSL signalling plays a key regulatory role in cardiac pathology. Whereas ICOS inhibition appears to attenuate fibrotic progression, ICOSL blockade accelerates fibrosis, cardiac dysfunction, and adverse remodelling. These data underscore the complex, cell-specific actions of co-stimulatory immune checkpoints in non-immune cells and suggest that modulating this pathway is a promising therapeutic strategy for heart failure.
Reference Key
openalex_W7172317767 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Z S Hegedus, M Jakab, P Ferdinandy, Z V Varga
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.241
URL
https://doi.org/10.1093/eurheartjsupp/suag097.241
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.